SINOVAC's Hepatitis A Vaccine Healive® Launched in Indonesia
2022-12-06

December 6, 2022, Jakarta -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its inactivated hepatitis A vaccine, Healive®, has been launched in Indonesia, under the cooperation with its local partner, PT Etana Biopharmaceutical Indonesia.

 

As one of SINOVAC's flagship products, Healive® is the first and only hepatitis A vaccine from China, which passed the assessment under WHO Prequalification Procedures. It offers sustained protection for 30+ years after full-course immunization, based on output of statistical modeling1.

 

Healive® was approved by BPOM, the food and drug agency of Indonesia, in February 2022. Including Indonesia, the Company's hepatitis A vaccine has been registered in 21 countries and organizations around the world and authorized to be administered in 33 countries and regions, to susceptible people aged over 12 months.

 

According to the World Health Organization's report, the Southeast Asia region had the greatest number of estimated hepatitis A cases and deaths between 2010 and 2019.

 

The hepatitis A disease is a public health challenge in Indonesia. The lower prevalence of anti-HAV among children on the island of Java had caused more frequent hepatitis A outbreaks. Currently, children and adults are recommended to take a 2-dose treatment of hepatits A vaccination by local healthcare organizations in Indonesia that include the Indonesian Pediatric Society and Indonesian Society of Internal Medicine.

 

 

Reference:

1.      Yu, YP, Chen, JT, Jiang, ZW, et al. Modeling the Long-term Antibody Response and Duration of Immune Protection Induced by an Inactivated, Preservative-free Hepatitis A Vaccine (Healive) in Children. BIOMED ENVIRON SCI. 2020; 33 (7): 484-492. doi: 10.3967/bes2020.065

 

About SINOVAC

 

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

 

SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, mumps, etc.

 

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

 

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

 

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

 

For more information, please see the Company’s website at www.sinovac.com.

 

 

 

Contact:

 

Sinovac Biotech Ltd.

 

PR Team

 

pr@sinovac.com

 

 


© SINOVAC